IndiaUS drive 2QFY25 performance while Brazil drags

Company
28 Oct 2024
5 Min read 
  • Torrent Pharma's 2QFY25 results update and financials.
  •  Sales, EBITDA, and adjusted PAT growth in 1HFY25.
  •  Management commentary on gross margin levels and future expectations.
  •  Product mix and profitability improvement efforts.
  •  US, India, Brazil, and Germany sales performance and growth expectations.
  •  Financial ratios, valuations, and future outlook.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities